Citations

Clear

3042 citation(s) found for "Kumar, S".

Surface protein-focused gene expression analysis identifies prognostic immunophenotypes in newly diagnosed multiple myeloma
Bohra, Arwa , Dasari, Surendra, Zanwar, Saurabh , Kumar, Shaji, Binder, Moritz , Steinauer, Nickolas , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Kumar, Shaji

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7477-7477

10.1182/blood-2025-7477 Get It

Abstract Introduction Surface proteins in cancer not only reflect tumor–microenvironment interactions but also serve as targets for diagnostic flow cytometry and precision therapies, including monoclonal antibodies and CAR-T cell therapies. A better understanding of plasma cell immunophenotypes could inform flow cytometric prognostic assays and development of targeted therapies. Methods RNA-seq and Seq-FISH data from CD138-enriched bone marrow plasma cells, along with corresponding clinical annotations, were obtained from the Multiple Myeloma Research Foundation-CoMMpass Study. A curated list of surface genes was assembled by integrating three sources: the Human Protein Atlas (plasma membrane and cell junction annotations), the Gene-Set Enrichment Analysis membrane-associated gene set (Ontology:0016020), and the Cell Surface Protein Atlas (validated high-confidence category). A total of 4,579 genes coding for cell surface proteins were identified. Genes below the 25th variance percentile were removed. PCA (≥90% variance) followed by k-means (k=2, silhouette) and confirmed by hierarchical clustering. A Plasma Cell Maturity (PBM) score was computed using singscore on 84 mature plasma cell–associated genes to compare cluster phenotypes. Pathway analysis was done using GSEA software for Hallmark pathways. Clinical biomarkers and survival kinetics were compared between the clusters. Results 761 newly diagnosed patients were included. (Age: 27-93 years, median overall survival/OS: 29 months/mo). Clustering revealed two groups which we termed Atypical/Aggressive Cluster 1 (C1, n=105, 13.8%) and Classical Cluster 2 (C2, n=656, 86.2%), based on the patterns and clinical characteristics. Among non-missing cases, high-risk disease per the International Myeloma Society–International Myeloma Working Group (IMS–IMWG) definition was observed in 27.7% of patients in C2 (n = 552) and 24.7% in C1 (n = 90) (p = 0.4).C1 exhibited enrichment for t(14;16)-MAF (OR = 2.6, 95% CI: 1.1–6.1, p = 0.04) and t(11;14)-CCND1 (OR = 1.7, CI: 1.01–2.8, p = 0.04). In contrast, hyperdiploidy was more common in C2 (OR for C1 = 0.6, CI: 0.4–0.9, p = 0.04). Elevated LDH was observed in C1 (OR = 2.6, CI: 1.6–4, p < 0.001). Median serum Beta-2 microglobulin was lower in C1.(p=0.009) Upregulated genes in C1 in decreasing order of log Fold Change(logFC): AHNAK, MT-ND1, EEF2, EZR, HLA-B, TXNIP, HLA-E, TRIB1, MCL1, RHOB, CD74, CFLAR, HLA-A, HERPUD1, RPSA, ERN1, HSP90AB1, RAPGEF2, ADGRE5, and LAPTM5. Downregulated genes in C1 in descending order of |logFC|: B2M, SDC1 (CD138), HSP90B1, SEL1L, CALR, CANX, PECAM1, SLAMF7, STT3A, TNFRSF17 (BCMA), FCRL5, STT3B, PALM2AKAP2, CD53, PARP1, CCR2, RPN1, CD38, EDNRB, and LMAN2. Upregulated pathways in C1: proliferation (MYC, E2F, PI3K/AKT/mTOR, KRAS, Wnt); evasion of apoptosis (p53, TGF-β, Notch, NF-κB, IL6/JAK/STAT3); Epithelial to Mesenchymal Transition (angiogenesis, apical junction); inflammatory (interferon, TNF-α, complement, IL2/STAT5); metabolic reprogramming (oxidative phosphorylation, lipid/cholesterol); and stress (DNA repair, unfolded protein response). The PBM score for C1 was significantly lower, suggesting a less differentiated phenotype. C1 patients had inferior survival (n = 93, median OS 43.9 mo, p = 0.04) compared to those in the C2 cluster (n = 559, median OS 102.5 mo). Patients in the C1 + IMS–IMWG high-risk status had the shortest survival (20.7 mo), compared to C1+low (50 mo), C2/high (68.3 mo), and C2+low (not reached). In a multivariable analysis, C1 status (HR = 1.93; 95% CI: 1.1–3.4, p = 0.02) was an independent predictor, along with older age (1.05), UAMS70 (1.02), EMC-92 (1.4). In C1, early (<18 mo) progression occurred in 76.3% (n=71) (p < 0.001). In patients receiving first line of treatment(LOT1), median PFS was 39.7 mo in C1vs. 47.3 mo in C2 (p=0.8). Among patients who received stem cell transplant in LOT1, the median survival for the C2 was 102.5 mo, compared to 44.5 mo for C1 (n = 52) (p = 0.01). Among non-SCT patients on Immunomodulator + Proteasome Inhibitor therapy, C1 (n=28) had shorter survival of 50.0 vs. 71.7 C2 (n=137; p =0.8). Conclusion Our transcriptomic analysis identified a higher-risk group of patients (C1) exhibiting downregulation of myeloma specific markers (CD38, CD138, BCMA, SLAMF7, FCRL5) and inferior outcomes. It is important to diagnose and find appropriate therapy for these patients as they don't obtain the same benefit from the current standard of therapy as the remaining patients.
Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma
Peres, Lauren C. , Zanwar, Saurabh , Richards, Alicia, Gaballa, Mahmoud , Afrough, Aimaz , Reid, Brett M. , Goel, Utkarsh , Sannareddy, Aishwarya , Ferreri, Christopher J. , Varga, Cindy , Hosoya, Hitomi , Mikkilineni, Lekha , Kalariya, Nilesh, Mikulski, Damian , Cahoon, Christopher, Cheng, Peter K.C. , Gordillo, Christian , Bhurtel, Jenny , Cassano, Raffaella Cassano , Midha, Shonali , Gonzalez, Rebecca , Purvey, Sneha , Green, Kimberly , Liu, Hien , Khouri, Jack , Bal, Susan, Freeman, Ciara L. , Shune, Leyla , Shain, Kenneth H. , Alsina, Melissa , Sborov, Douglas W. , Voorhees, Peter M. , Costa, Luciano da Fontoura , Biran, Noa , Kumar, Shaji , Lin, Yi, Sidana, Surbhi , Patel, Krina K. , Davis, James A. , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Hansen, Doris K. , Dima, Danai , Puglianini, Omar Castañeda , Pasvolsky, Oren , Grajales‐Cruz, Ariel , Xie, Zhuoer , Dillard, Christen , Atrash, Shebli , Portuguese, Andrew J. , Wagner, Charlotte B , Zolotov, Eli , Kort, Jeries , Davis, James, Herr, Megan M. , Hassan, Hamza , Geer, Marcus , Green, Kimberly, Perna, Fabiana , Nishihori, Taiga , Raza, Shahzad , Anwer, Faiz , Bal, Susan , Nadeem, Omar , Banerjee, Rahul , Reshef, Ran , Baz, Rachid , Anderson, Larry D. , Costa, Luciano, Biran, Noa , Locke, Frederick L.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 93-93

10.1182/blood-2025-93 Get It

Abstract Introduction Ciltacabtagene autoleucel (cilta-cel) has demonstrated unprecedented response rates and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM), but a proportion of patients experience early relapse. Identifying these patients is essential to guide future therapeutic strategies, such as enhanced bridging therapy or consolidation, while avoiding overtreatment in those likely to achieve durable disease control. Methods We conducted a multi-center study of patients treated with cilta-cel at 15 U.S. academic centers. Outcomes were evaluated based on high-risk (HR) features, including functional HR disease (FHR; relapse within 18 months of first-line therapy initiation), true extramedullary disease (EMD), traditional HR cytogenetics as defined in CARTITUDE-1 [deletion 17p, t(4;14), t(14;16)], and a 2024 IMS-IMWG-adapted HR definition (deletion 17p; t(4;14) or t(14;16) with gain 1q or deletion 1p; and gain 1q with deletion 1p). Multivariable Cox regression was used to examine the association of HR features (FHR, adapted IMS-IMWG HR, and EMD, individually and collectively) with PFS while adjusting for baseline ferritin, prior BCMA, and ECOG performance status (PS ≥2). Among patients with ≥18 months of follow-up, we evaluated predictors of early relapse (≤18 months post infusion) using logistic regression. Results Our cohort included 598 patients treated with cilta-cel between 5/2022 and 12/2024 who had available data on all HR features. The median age was 65 years (range 33-83), and the median prior lines of therapy (pLOT) was 5 (range: 1-18, 84% with >3 pLOT); 8% had received prior BCMA-directed therapy, and 27% were penta-refractory. Most patients (88%) received bridging therapy and 30% achieved ≥ partial response. In our cohort, 33% (n=195) had FHR, 43% (n=258) had traditional HR cytogenetics, 42% (n=253) had adapted IMS-IMWG HR disease, and 11% (n=64) had EMD. Median follow up was 10.6 months (range 0.4-34.1). Overall response rate (ORR) and complete response (CR) rates were lower in patients with vs without HR features: FHR (ORR: 89% vs 94%, CR: 61% vs 75%), traditional HR (ORR: 90% vs 94%, CR: 65% vs 74%), adapted IMS-IMWG HR (ORR: 91% vs 94%, CR: 64% vs 75%) and EMD (ORR: 77% vs 94%, CR: 61% vs 71%). Corresponding 12-month PFS was also lower in patients with vs without HR features: FHR (55% vs 79%), traditional HR (63% vs 78%), adapted IMS-IMWG HR (61% vs 80%) and EMD (59% vs 73%). ORR, CR rate, and 12-month PFS in patients without any HR features compared to those with ≥1 HR feature were 96% vs 90%, 81% vs 64%, and 83% vs 65%, respectively. In multivariable models, each HR feature (FHR, adapted IMS-IMWG HR, and EMD) was independently associated with inferior PFS after adjusting for baseline ferritin, prior BCMA, and ECOG PS ≥ 2. However, because early relapse cannot always be identified a priori based on traditional risk factors, we sought to identify predictors of relapse within 18 months of cilta-cel in a subset of patients with ≥18 months of follow-up (N=247; infused by 12/2023). Notably, while FHR (OR=3.04, 95% CI=1.59-5.89) and adapted IMS-IMWG HR (OR=2.07, 95% CI=1.10-3.89) were independently associated with odds of relapse within 18 months, EMD was not (OR=0.90, 95% CI=0.32, 2.40) when accounting for prior BCMA, ECOG PS ≥ 2, and baseline ferritin. We also used a time-varying Cox model to examine each HR feature associated with PFS at two time periods, <18 and ≥18 months, while adjusting for baseline ferritin, ECOG PS, and prior BCMA. We confirmed that FHR and adapted IMS-IMWG HR were both associated with relapse <18 months (HR=2.05, 95% CI=1.48-2.83 and HR=1.56, 95% CI=1.11-2.19) but not in the ≥18-month time period (HR=0.70, 95% CI=0.19-2.59 and HR=0.76, 95% CI=0.24-2.40). The magnitude of the association for EMD with PFS was similar across both time periods (<18 months HR=1.67, 95% CI=1.09-2.57 and ≥18 months HR=2.17, 95% CI=0.45-10.40). Conclusion While cilta-cel leads to high response rates and durable PFS in RRMM, a subset of patients with FHR and adapted IMS-IMWG HR remains at increased risk for early relapse. In this large multi-center cohort, we describe PFS outcomes across high-risk subgroups and identify key predictors of relapse within 18 months of cilta-cel. These findings inform risk-adapted therapeutic strategies and interventional trials, including bridging, consolidation, or maintenance approaches, to improve outcomes in the highest-risk RRMM patients.
Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study
Li, Katherine , Lin, Yi , Martin, Thomas G. , Han, Siyu, de, Rocío Montes , Suraneni, Mahipal, Hodkinson, Brendan P. , Wang, Feng, Kumar, Ashwini , Yin, Da , Smirnov, Denis A. , Patel, Jaymala , Lendvai, Nikoletta , Zhu, Jieqing, Koneru, Mythili, Patel, Nitin , Geng, Dong , Plaks, Vicki , Parekh, Samir , Donk, Niels W.C.J. van de , Han, Siyu, Gormley, Michael , Yuan, Jinzhou , Wang, Feng , Yin, Da, Madduri, Deepu , Harrison, Simon J

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 92-92

10.1182/blood-2025-92 Get It

Abstract Introduction: Cilta-cel is approved in the US and the EU for the treatment of patients (pts) with lenalidomide-refractory multiple myeloma (MM) after ≥1 prior line of therapy (pLOT), including a proteasome inhibitor and an immunomodulatory agent based on the CARTITUDE-1 (CART-1, NCT03548207) and CARTITUDE-4 (CART-4, NCT04181827) studies. Cilta-cel led to deep and durable responses and significant survival benefit in pts with relapsed/refractory MM (RRMM) after ≥3 pLOT in CART-1. In CART-4, cilta-cel led to a significant overall survival benefit with a higher proportion of pts achieving deep, sustained minimal residual disease negativity vs standard of care in pts with lenalidomide-refractory MM after 1–3 pLOT. We investigated the mechanism of action of cilta-cel by correlating biomarkers from peripheral blood and the bone marrow TME with progression-free survival (PFS) and number of pLOT in pts with RRMM from CART-1 and CART-4. Methods: Biomarker analyses were performed using peripheral blood and bone marrow aspirates (BMAs) collected in both CART-1 and CART-4 studies. Immunophenotyping by flow cytometry was performed using peripheral blood at baseline/time of apheresis in samples from both studies. Immune fitness at baseline was assessed in pts by pLOT and in association with PFS. Gene set enrichment scores were derived from RNA sequencing data of the TME using BMAs. Mixed-effects models were used to identify signatures/pathways modulated over time (day [D] 28 and at 6 months [mo] post infusion vs screening) and in association with PFS and pLOT. Results: In total, 176 CART-4 and 97 CART-1 pts received cilta-cel as study treatment. Immunophenotyping data were available from 248 peripheral blood samples (1 pLOT, n=56; 2 pLOT, n=61; ≥3 pLOT, n=131). At apheresis, CD4+ naïve T cells (%) were higher in pts with 1 or 2 pLOT, compared with those with ≥3 pLOT, while no difference was found in pts with ≥3 pLOT with further breakdown (i.e., 3–4 vs 5–6 vs ≥7 pLOT). Further, higher baseline levels of CD4+ naïve T cells were associated with longer PFS. These data suggest that the negative impact on peripheral immune fitness with the addition of LOT may plateau when pts have received ≥3 pLOT. TME gene expression data were available from 148 BMA samples (screening, n=50; D28, n=50; 6 mo, n=48) from CART-4. Analyses of gene expression signatures suggest depletion of B cells and antibodies at D28 post cilta-cel infusion, with partial recovery at 6 mo. This was corroborated in parallel by flow cytometry and immunoglobulin quantification. Further, elevated expression of genes associated with myeloid cells, including tumor-associated macrophages (TAM, likely M1), and of genes associated with cytotoxic T cells were also observed at D28. Elevated expression of genes associated with B-cell receptors, T-cell differentiation and activation, and cytokine signaling pathways were found at both D28 and 6 mo. Pts with longer PFS (>18 mo) had higher levels of M1 TAM at D28, while those with shorter PFS had higher levels of regulatory T cells and more suppressed interferon pathway genes at 6 mo, suggesting that relapse may be associated with a more suppressive immune response. In pts with fewer pLOT, more profound B-cell depletion on D28, better recovery at 6 mo, and elevated B-cell receptor signaling were inferred from gene expression data. Pts with 1 pLOT also demonstrated higher elevation of M1 TAM expression on D28 from screening as compared with pts with 3 pLOT, similar to what was observed in pts with longer PFS. Conclusions: Correlative biomarker data suggest that longer PFS is associated with better immune fitness at baseline and stronger immune responses post cilta-cel infusion, as observed in peripheral blood and within the TME of pts with RRMM in CART-1 and CART-4. The peripheral immune fitness was more pronounced in pts with 1 and 2 pLOT vs 3 pLOT and beyond, where deterioration plateaued. This suggests the impact of T-cell immune fitness on PFS may be limited beyond the third LOT. Importantly, other covariates, including factors within the immune TME and tumor burden, may play a significant role in balancing this compromised intrinsic T-cell immune fitness at apheresis, thereby contributing to PFS durability after 3 pLOT. Overall, these results support increased benefits in treating pts with MM with cilta-cel in earlier LOTs.
Lymphovision: A lymphoma-specialized foundation model for histology-based lymphoma classification and subtyping
Seheult, Jansen N. , Han, Wenchao, Keser, Reyhan Kevser , Sapkota, Nishchal, Kumar, Nilesh, Mwangi, Raphael , Dalland, Joanna , Larson, D. J., Zhang, Chi , Dangott, Bryan, McClintock, David S. , Reed, Katelyn A. , Schwartz, Kaitlin, Bjorheim, Annette, Lee, Jodi, Halvorson, J. Derek, Nowakowski, Grzegorz S. , Ansell, Stephen M. , King, Rebecca, Seheult, Jansen N , Tavolara, Thomas Erol , Kumar, Nilesh, Larson, Daniel, Gibson, Sarah E. , Horna, Pedro , Schwartz, Kaitlin, Lee, Jodi, Halvorson, Joseph, Witzig, Thomas E. , Maurer, Matthew J. , Cerhan, James R. , Hsi, Eric D.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 117-117

10.1182/blood-2025-117 Get It

Abstract Background: Recent advances in computer vision have given rise to image foundation models (FMs), large-scale neural networks pre-trained on millions of unlabeled histopathology patches, which can learn generalizable representations of tissue morphology. In many cancers, these FMs have predicted genetic mutations and prognoses directly from histology, suggesting that morphology encodes “hidden” molecular information. In lymphoma, this field is nascent but growing.General-purpose histopathology FMs have limited representation of lymphoid morphology. We developed and evaluated LymphoVision, a lymphoma-specialized image foundation model pretrained with self-supervised learning, to extract clinically meaningful features from routine hematoxylin and eosin (H&E) histology. Methods: LymphoVision was pre-trained using knowledge distillation and consistency (DINOv2) on over 37 million multi-resolution patches (5x, 10x, 20x, 40x) sampled using a density-aware strategy from 31,211 H&E whole slide images (WSIs) from 9,155 archival lymphoma and reactive lymphoproliferative cases. To ensure diverse, representative samples, our patch sampling method uses an efficient graph-based clustering algorithm and prioritizes morphologically informative regions by clustering patch embeddings and performing density sampling within each cluster. The pretrained encoder was evaluated using a clustering-constrained attention multiple instance learning (MIL) framework on three diagnostic tasks: (1) cell-of-origin (COO) classification in diffuse large B-cell lymphoma (DLBCL), distinguishing germinal center B-cell (GCB) from non-GCB subtypes based on the Hans immunohistochemistry algorithm; (2) follicular lymphoma (FL) grading, differentiating low-grade (grades 1–2) from high-grade (grade 3); and (3) multiclass lymphoma subtype classification across six categories: DLBCL, FL, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), classical Hodgkin lymphoma (CHL), and benign/reactive lymphoid conditions. WSI-level labels were derived from pathology reports, and none of the evaluation cases were included in pretraining. Models used a ViT-Giant LymphoVision backbone to generate 20x patch embeddings, followed by MIL using 50% training data and 2-fold cross-validation (25% validation, 25% test). Performance was assessed using area under the receiver operating characteristic curve (AUC), accuracy, recall (sensitivity) and F1 score. Results: For DLBCL COO classification (total n=358 cases), LymphoVision achieved a mean test AUC of 0.93 (range 0.92–0.94), accuracy of 84.5% and F1 of 0.85 across two independent test folds (n=91 per fold, 50% GCB). These results outperformed general-purpose FMs on the same task and cases, including Virchow-v2 (AUC 0.85) and UNI-v2 (AUC 0.88), despite those models being pretrained on 10–100 times more images. For FL grading (total n=660 cases), the test set in each fold included 166 cases (18% grade 3), yielding a mean test AUC of 0.88 (range 0.87–0.90), accuracy of 89.2% and F1 of 0.80. In multiclass lymphoma subtype classification (total n=1,176 cases), the test set included 296 cases per fold. LymphoVision achieved a mean test AUC of 0.98 (range 0.97-0.99), mean test accuracy of 87.1% and mean F1 of 0.84. Class-wise recall was 92.0% for DLBCL (n=112), 88.2% for FL (n=72), 77.2% for MZL (n=29), 70.8% for MCL (n=35), 87.5% for CHL (n=24), and 95.8% for benign/reactive lymphoid conditions (n=24). Conclusion: LymphoVision is a lymphoma-specialized FM trained using self-supervision that achieves high diagnostic accuracy across multiple clinically meaningful tasks using weak supervision and standard H&E images, suggesting the encoder has learned fine-grained lymphoma morphology. Based on historical benchmarks from the 1997 International Lymphoma Study Group classification project, expert hematopathologists achieved diagnostic agreement rates of 55% to 84% using H&E morphology alone for the non-Hodgkin lymphoma (NHL) entities included in our multiclass task. LymphoVision approached or exceeded these benchmarks. These findings underscore the value of our approach using disease-specialized pretraining and intelligent patch sampling for data-efficient histopathology learning. LymphoVision has the potential to augment diagnostics, enable scalable AI-powered classification in real-world workflows, and serve as a foundation for prognostic and theragnostic applications. External validation and multimodal integration are ongoing.
Talquetamab outcomes in relapsed/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas
Afrough, Aimaz, Pasvolsky, Oren, Zanwar, Saurabh, Gaballa, Mahmoud, Sannareddy, Aishwarya, Dima, Danai, Goel, Utkarsh, Ali, Hossam M., Julian, Kelley, Corraes, Andre, Cassano, Raffaella, Janakiram, Murali, Goldsmith, Scott, Davis, James, Green, Kimberly, Biran, Noa, Fogel, Lindsay, Zolotov, Eli, Herr, Megan, Hassan, Hamza, Shune, Leyla, Kort, Jeries, Bal, Susan, Costa, Luciano, Ye, J Christine, Joiner, Laura, Raza, Shahzad, Anwer, Faiz, Khouri, Jack, Banerjee, Rahul, Portuguese, Andrew, Sidana, Surbhi, Rana, Masooma, Mikkilineni, Lekha, Hosoya, Hitomi, Atrash, Shebli, Ferreri, Christopher, Varga, Cindy, Sborov, Douglas, Midha, Shonali, Nadeem, Omar, Grajales-Cruz, Ariel, Baz, Rachid, Blue, Brandon, Freeman, Ciara Louise, Locke, Frederick, Patel, Krina, Lin, Yi, Kumar, Shaji, Hansen, Doris, Anderson, Larry, Voorhees, Peter, Puglianini, Omar Alexis Castaneda, Sidana, Surbhi , Hosoya, Hitomi , Davis, James A. , Ali, Hossam M. , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Ali, Hossam M , Sannareddy, Aishwarya , Afrough, Aimaz, Pasvolsky, Oren, Zanwar, Saurabh, Gaballa, Mahmoud, Dima, Danai, Goel, Utkarsh, Ali, Hossam M., Julian, Kelley, Corraes, Andre, Cassano, Raffaella, Janakiram, Murali, Goldsmith, Scott, Davis, James, Green, Kimberly, Biran, Noa, Fogel, Lindsay, Zolotov, Eli, Herr, Megan, Hassan, Hamza, Shune, Leyla, Kort, Jeries, Bal, Susan, Costa, Luciano, Ye, J Christine, Joiner, Laura, Raza, Shahzad, Anwer, Faiz, Khouri, Jack, Banerjee, Rahul, Portuguese, Andrew, Rana, Masooma, Mikkilineni, Lekha, Atrash, Shebli, Ferreri, Christopher, Varga, Cindy, Sborov, Douglas, Midha, Shonali, Nadeem, Omar, Grajales-Cruz, Ariel, Baz, Rachid, Blue, Brandon, Freeman, Ciara Louise, Locke, Frederick, Patel, Krina, Lin, Yi, Kumar, Shaji, Hansen, Doris, Anderson, Larry, Voorhees, Peter, Puglianini, Omar Alexis Castaneda

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 825-825

10.1182/blood-2025-825 Get It

Abstract Background: Talquetamab (Talq), a GPRC5D-targeting bispecific antibody, shows promising activity in relapsed/refractory multiple myeloma (RRMM). However, outcomes in patients (pts) with soft tissue plasmacytoma (STP) remain poorly characterized. Method: We retrospectively analyzed 463 RRMM pts treated with Talq at 15 U.S. centers by Dec 2024. Pts were grouped by presence of STP at Talq start: (1) extramedullary disease (EMD; lesions not contiguous with bone), (2) paraskeletal disease (PSK; bone-contiguous), (3) EMD + PSK, and (4) No-STP. Those receiving Talq as a bridge-to-CAR T (n=103, 22%) were censored at CAR T infusion if progression had not occurred. Time-to-event endpoints were calculated from Talq step-up, using Kaplan-Meier/Cox models. Result: Median age was 66 years (y) (35–89); 54 (11.7%) had EMD, 26 (5.6%) PSK, 60 (13%) EMD+PSK, and 320 (69%) No-STP. EMD pts were younger than No-STP (62 vs 66 y, p=.009), while PSK (66.5) and EMD+PSK (64.5) were similar to No-STP. Median prior lines were higher in PSK (7) vs EMD (5), EMD+PSK (6) and No-STP (6) (p=.035). Median time from diagnosis to Talq was shortest in EMD (3.8 y), followed by EMD+PSK (4.6 y), vs PSK (6.4 y), and No-STP (5.9 y) (p=.015). Among pts with any EMD (EMD or EMD+PSK), 81 (69%) had visceral involvement and 85 (73%) had multiple lesions. Rates of prior BCMA- or GPRC5D-directed therapy, plasma cell leukemia (≥5% circulating plasma cells at the time of Talq), and penta-refractoriness were similar across groups. ECOG ≥ 2 at Talq was more common in EMD (42%), PSK (39%), EMD+ PSK (37%) than in No-STP (23%) (p = .002). Other baseline features were similar. Cytokine release syndrome (CRS) rate/severity were similar across groups. The immune effector cell–associated neurotoxicity syndrome (ICANS) was more frequent in PSK (38%) vs EMD (11%), EMD + PSK (18%), and No-STP (11%), with the most PSK cases (60%, 6/10) being grade ≥2 (p=.006). No difference in CRS/ICANS onset or duration. Infection rates were lower in No-STP (36%) vs EMD (55%), PSK (46%), and EMD+ PSK (48%) (p=.025). Best overall response rates (ORR) were 71% in EMD, 68% in PSK, 67% in EMD+PSK, and 71% in No-STP (p=.9). Complete response (CR) rates were 14% in EMD, 20% in PSK, 13% in EMD+ PSK, and 25% in No-STP (p=.1) [CRs were not required to be confirmatory, which may not meet full IMWG criteria]. Radiographic response was evaluable in 41 EMD (86%), 16 PSK (61.5%), and 48 EMD+PSK (80%) pts, with partial response (PR) or better observed in 48%, 27%, and 38%, respectively. Among pts with any STP, 34% received radiation (XRT) (4 as bridge-to-CAR T), 24 (51%) were evaluable, and 71% (n=17) achieved ≥PR. The median follow-up from Talq initiation was 10.1 months (mo) (95% CI: 8.8–11.4) and was longest in EMD (13.9 mo) compared with PSK (10.8 mo), EMD+PSK (12.4 mo), and No-STP (9.8 mo) (p = .040). Median progression-free survival (PFS) was 4.3 mo (95% CI: 3.6–5.06) in EMD, 4.8 mo (95% CI: 2.2–7.3) in PSK, 3.8 mo (95% CI: 3.1-4.5) in EMD+ PSK, and 8.3 mo (95% CI: 7.0–9.6) in No-STP (p <.001). Among pts receiving XRT for any STP (within 4 weeks prior to or during Talq), responders had longer PFS vs non-responders (15.4 vs. 2.4 mo; p=.009). Multivariable analysis (MVA) showed inferior PFS with EMD (Hazard Ratio (HR) 1.58; 95% CI, 1.04-2.3; p=.029), EMD+PSK (HR 1.91; 95% CI, 1.2–2.8; p = .001), ECOG ≥ 2 (HR 1.4; 95% CI, 1.04–1.9; p = .024), and del(17p) at any timepoint (HR 1.99; 95% CI, 1.1–3.5; p=.017), while longer time from diagnosis to Talq was modestly protective (HR 0.95 per year; p = .016), likely reflecting less aggressive biology in those reaching 5th+ line later. PSK alone showed a non-significant trend toward inferior PFS (HR 1.5; p = .1). Median overall survival (OS) was 13.0 mo (95% CI: not reached [NR]–NR) in EMD, 12.9 mo (95% CI: 6.9–18.9) in PSK, 10.9 mo (95% CI: NR–NR) in EMD+PSK, and NR (95% CI: NR–NR) in No-STP (p = .017). The primary cause of death was disease-related across all groups (p = .6). MVA for OS showed worse outcomes with EMD+PSK (HR 1.7; p=.033), ECOG ≥ 2 (HR 1.98; p <.001), and active PCL at Talq (HR 2.1; p =.010). Conclusion: Soft tissue plasmacytoma, particularly EMD and EMD+PSK, remain strong adverse prognostic factors in Talq-treated patients, with significantly shorter PFS and OS despite similar response rates. Radiation to STP sites was associated with improved outcomes in select cases. Prospective strategies are needed to optimize management for this high-risk population.
Cytokine score for prognostication of newly diagnosed multiple myeloma
Bohra, Arwa, Dasari, Surendra, Binder, Moritz, Zanwar, Saurabh, Gonsalves, Wilson, Rajkumar, S. Vincent, Kumar, Shaji, Bohra, Arwa, Dasari, Surendra, Binder, Moritz, Zanwar, Saurabh, Gonsalves, Wilson, Rajkumar, S. Vincent, Kumar, Shaji

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7463-7463

10.1182/blood-2025-7463 Get It

Abstract Introduction Multiple myeloma (MM) is clinically heterogeneous, and therapeutic response is profoundly influenced by the complex cytokine milieu of the bone marrow microenvironment. Unlike most cancers, MM staging incorporates non–tumor-burden markers such as serum albumin, β₂-microglobulin, and LDH, which are prognostically useful but biologically nonspecific. Although individual cytokines (e.g., IL-6, IL-17, TGF-β) have been linked to disease activity, a comprehensive, systems-level assessment comparing an exhaustive list of cytokines, chemokines, and growth factors across large patient cohorts is lacking. Here, we present evidence for an actionable cytokine panel, using gene expression–derived cytokine bioactivity as a surrogate measure. Methods CD138 enriched bone marrow plasma cell RNA-seq, Seq-FISH, and clinical data were obtained from the MMRF CoMMpass study. Data were TMM-normalized, log₂(x + 1) transformed, and mean-centered. Bioactivity scores for 64 cytokines, chemokines, and growth factors were inferred using CytoSig (National Cancer Institute). CytoSig leverages transcriptomic data from over 20,000 samples treated with individual molecules to model gene expression changes of cytokine regulators, targets, and response elements to provide z-scores. Reverse validation of bioactivity between samples scoring top and bottom quartiles of each cytokine was done using pathway analysis via Gene Set Enrichemnent analysis platform that verifies bioactivity across 7561 well-studied gene sets.(MSigDB C2 2025). Cytokines with upregulation of associated pathways were considered for downstream analyses (Criteria: Normalized enrichment score > 1). Genes were ranked by sign(logFC) × –log₁₀(p), identifying 44 significantly enriched pathways. Univariate Cox regression identified prognostic cytokines. To account for variable correlation and improve prediction, Elastic Net Cox regression (α = 0.5) was used, combining LASSO (L1) and Ridge (L2) penalties. For biological validation, pathway analysis was done between samples with high vs low serum C-Reactive Protein(CRP). Survival kinetics and clinical characteristics were analyzed for the derived model. Results A total of 767 NDMM patients were included (median age 63 years, range 27–93); median overall survival (OS) was 44.4 months (IQR 70.9). Revised International Staging System (R2-ISS) distribution was: Stage I 14.7%, II 24.0%, III 34.7%, and IV 6.4%. Based on the International Myeloma Society–International Myeloma Working Group (IMS–IMWG) definition, 32.2% of patients were classified as high-risk. Supervised analysis identified 30 univariate prognostic cytokines. Elastic Net retained BMP-7, IGF-1, IL-3, NRG1, IL-17A, IL-2, IL-21, and TGF-A (positive coefficients), and IL-4, IL-18, BMP-4, palmitic acid, DHT, and BMP-2 (negative coefficients). In sensitivity analysis, after removing cytokines not passing GSEA validation, the cytokine score (CS) was established using BMP-7, IL-3, TGF-A, IL-17A, BMP-2, IL-18, BMP-4, and IL-4. High serum CRP–associated gene expression was linked to upregulation of IL-17 and BMP pathways and downregulation of IL-4 signaling. Patients with CS ≥ median had higher β2M (p < 0.001) and LDH (p = 0.005); creatinine (p = 0.07) and albumin (p = 0.6) were not significant. CS was higher in patients with del(17p), 1q21 gain, high-risk IGH, t(8;14), and del(1p), and lower in those with hyperdiploidy (all p < 0.01). CS achieved a C-index of 0.67. Median OS was 58.7 months in the high-CS group vs. 102.5 months in the low-CS group (p < 0.001). Adding continuous CS to a model with continuous β2M + continous albumin improved C-index from 0.65 to 0.72. ISS improved from 0.62 to 0.68; R2-ISS from 0.65 to 0.69. A multivariate model with β2M ≥ 5.5, del(1p) + 1q gain, t(4;14), deep del(1p), and del(17p) improved from 0.63 to 0.68 with CS. Discussion These findings require functional validation in patient samples through direct measurement of cytokine levels. BMP-7 remains understudied in MM. Elevated TGF-α, IL-3, and IL-17 promote angiogenesis, bone resorption, and immune dysfunction, while BMP-2 and BMP-4 act as tumor suppressors. IL-18 is being utilised to boost T-cell responses, and IL-4 is consistently reduced in MM. Conclusion This study provides evidence for a robust, clinically translatable cytokine, chemokine, and growth factor panel. IL-17, IL-4, and BMPs emerged as consistently regulated across all analyses. CS is associated with high-risk disease and inferior survival.
Commpass explorer: An interactive platform to explore clinico-genomic data from newly diagnosed multiple myeloma patients from the commpass observational trial
Zhang, Wanxing, Acharya, Chaitanya, Foltz, Steven, Network, MMRF Immune Atlas, Avigan, David, Parekh, Samir, Vij, Ravi, Kumar, Shaji, Kourelis, Taxiarchis, Lonial, Sagar, Cho, Hearn, Vlachos, Ioannis, Gnjatic, Sacha, Ding, Li, Bhasin, Manoj, Mulligan, George, Zhang, Wanxing, Acharya, Chaitanya, Foltz, Steven, Network, MMRF Immune Atlas, Avigan, David, Parekh, Samir, Vij, Ravi, Kumar, Shaji, Kourelis, Taxiarchis, Lonial, Sagar, Cho, Hearn, Vlachos, Ioannis, Gnjatic, Sacha, Ding, Li, Bhasin, Manoj, Mulligan, George

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7470-7470

10.1182/blood-2025-7470 Get It

Abstract The CoMMpass study (NCT01454297) is a prospective, longitudinal observational trial involving 1,141 newly diagnosed, treatment-naïve multiple myeloma (NDMM) patients. Bone marrow aspirates from the study participants were collected, separated into CD138 negative and CD138 positive fractions for comprehensive molecular characterization of tumor (using bulk RNA sequencing and whole genome sequencing) and tumor immune microenvironment using 3' single-cell RNA sequencing (scRNA-seq). To support exploration of this rich multi-omic dataset, we developed CoMMpass Explorer (CE), an intuitive interactive platform that enables real-time analysis of clinical and genomic data from these study participants. CE provides four main views: Overall Summary for clinical feature distribution and Kaplan-Meier curves; Mutational Profile for visualizing and comparing somatic mutations; Tumor Profile for differential expression and gene set enrichment; and Immune Microenvironment for comparing cell type abundance and cell cycle dynamics between cohorts using scRNA-seq data. A central feature of CE is cohort building, where users can filter and stratify patients by clinical, genomic, and survival data elements to create custom cohorts for analysis. We validated CE by reproducing findings from two prior CoMMpass-based studies. In the first study by Simhal et al, we stratified patients using transcript-level expression by WEE1 into tertiles and confirmed that high WEE1 expression is associated with poorer progression-free survival across multiple genomic subgroups. In the second study by Manojlovic et al, we replicated mutation frequencies between African American and Caucasian patients by creating race-based cohorts. We further demonstrate CE's utility by identifying and comparing two NDMM cohorts of patients at baseline who have not received autologous stem cell transplant: cohort 1 includes patients that received up-front triplet therapy (N=342) and cohort 2 includes those who did not receive a triplet up-front (N=235). While survival differences between these two cohorts were not statistically significant (p>0.05), CE revealed elevated epithelial-mesenchymal transition (EMT) pathway activity in cohort 1. Immune profiling showed lower abundance of CD8+ T cells (p < 0.05) and NK cells (p = 0.01), but a higher abundance of B cells (p < 0.05) in cohort 1. Genomic data showed fewer EIF2AK3 mutations and higher transcript-level expression of EIF2AK3 in cohort 1. Notably, patients in cohort 1 with lower transcript-level expression of EIF2AK3 had better survival outcomescompared to patients in cohort 2. CE democratizes access to the CoMMpass multi-omic resource, allowing researchers to interrogate clinical and molecular heterogeneity with ease. By enabling hypothesis generation and replication of published results, CE serves as a valuable tool for identifying meaningful patterns in gene expression, mutation profiles, and immune contexture. It also highlights potential prognostic biomarkers, such as EIF2AK3 expression, that may inform treatment decisions in NDMM, especially in the context of triplet-based regimens.
Cardiac complete response in AL amyloidosis: Phenotypic characteristics, functional recovery, and survival outcomes of 63 patients
Muchtar, Eli, Geyer, Susan, Dispenzieri, Angela, Grogan, Martha, Kourelis, Taxiarchis, Buadi, Francis, Kapoor, Prashant, Dingli, David, Gonsalves, Wilson, Leung, Nelson, Merlini, Giampaolo, Rosenthal, Julie, Lyle, Melissa, Hayman, Suzanne, Lacy, Martha, Siddiqui, Mustaqeem, Cook, Joselle, Abdallah, Nadine, Binder, Moritz, Zanwar, Saurabh, Lin, Yi, Warsame, Rahma, Kyle, Robert, Rajkumar, S. Vincent, Kumar, Shaji, Gertz, Morie, Muchtar, Eli, Geyer, Susan, Dispenzieri, Angela, Grogan, Martha, Kourelis, Taxiarchis, Buadi, Francis, Kapoor, Prashant, Dingli, David, Gonsalves, Wilson, Leung, Nelson, Merlini, Giampaolo, Rosenthal, Julie, Lyle, Melissa, Hayman, Suzanne, Lacy, Martha, Siddiqui, Mustaqeem, Cook, Joselle, Abdallah, Nadine, Binder, Moritz, Zanwar, Saurabh, Lin, Yi, Warsame, Rahma, Kyle, Robert, Rajkumar, S. Vincent, Kumar, Shaji, Gertz, Morie

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3960-3960

10.1182/blood-2025-3960 Get It

Abstract Cardiac involvement in AL amyloidosis significantly impacts both short and long-term survival. Achieving cardiac complete response (CarCR) is linked to excellent survival, comparable to that of the general population. We undertook this study to characterize patients with AL amyloidosis who achieved CarCR. Methods: A single-center retrospective study of patients diagnosed with cardiac AL amyloidosis between 2004 and 2023 and achieved a documented CarCR for at least 12 months. Patients were included if they had evidence of cardiac involvement confirmed by cardiac imaging (transthoracic echocardiogram or cardiac magnetic resonance) and Congo red–positive tissue (non-cardiac or heart biopsy), and were evaluable for cardiac response based on baseline NT-proBNP > 650 pg/mL or BNP > 150 pg/mL. CarCR was defined as a reduction in NT-proBNP to less than 350 pg/mL (or BNP less than 80 pg/mL). Heart transplant patients were excluded. Results: Sixty-three patients were included, representing 4.6% of the cardiac evaluable population in the study period. This proportion increased in the second period compared to the first period (7.5% vs 3.2%, P<0.001). The median age at diagnosis of 57 years (ranging from 29 to 79); 63% were male. Lambda light chain disease was evident in 63% of patients. The median difference between the involved and uninvolved light chain (dFLC) at baseline was 429 mg/L (interquartile range [IQR] 143-708). While all patients had cardiac involvement, 63% also presented with extra-cardiac involvement [kidneys (52%), liver (16%), autonomic nerves (14%), luminal gastrointestinal tract (11%), and peripheral nerves (10%)]. The median baseline NT-proBNP for the entire cohort was 1977 pg/mL (IQR 1393-3026). The median troponin T (n=43) was 0.02 ng/mL (IQR <0.01-0.05) and the median high-sensitivity troponin T (n=19) was 49 ng/L (IQR 38-79 ng/L). Cardiac stage distribution, according to the European modification of the Mayo 2004 staging model, was as follows: 59% stage II, 39% stage IIIa, and 2% stage IIIb. At baseline, echocardiogram features included a median left ventricular (LV) ejection fraction of 63%, a median intraventricular septum thickness of 14 mm, and a median average LV longitudinal strain of -12%. The most common first-line therapies were autologous stem cell transplantation (ASCT; with or without induction, 54%), bortezomib-containing therapy (22%), and daratumumab-containing therapy (13%). Hematological complete response rates at 3-month, 6-month, and best response prior to CarCR were 32%, 49% and 76%, respectively. At CarCR, the median NT-proBNP was 265 pg/mL (IQR 220-307) with a median time from treatment onset to CarCR achievement of 20.6 months. At CarCR, 33% of patients were on loop diuretics. The CarCR rate at 6, 12, 24, 36, 48 and 60 months from treatment onset was 10%, 39%, 81%, 90%, 95% and 96%, respectively. Temporary increase of NT-proBNP above 350 pg/mL with return to CarCR was documented in 46% of patients. Echocardiogram parameters also improved significantly at the time of CarCR, with average left ventricular longitudinal strain showing the greatest median improvement in relation to baseline (from -12% to -17%, p<0.001). However, echocardiographic parameters did not fully normalize in all patients. Cardiac progression was seen in 14% of patients, at a median of 7.6 years from the initial time of CarCR. In addition, subsequent clone-directed therapy was given in 44% of patients at a median of 4.6 years from the initial treatment. With a median follow-up of 9.5 years, eight patients (13%) died, 4 due to causes unrelated to AL. We compared the survival of patients who achieved CarCR to the general U.S. population, matching for age, sex, and the year treatment. The observed survival of CarCR patients was similar to that of the general population (p=0.35). Conclusion: Patients with persistent CarCR >12 months in AL amyloidosis are uncommon and demonstrate excellent outcomes. The achievement of hematological CR was required in 3 out of 4 patients reaching a CarCR. Echocardiographic changes of amyloid infiltration may still persist in this highly favorable cohort, indicating that “complete” response refers primarily to functional and prognostic improvement, not necessarily a full restoration to pre-disease cardiac morphology and function. Achieving CarCR is associated with a low risk of cardiac progression, but the need for subsequent clone-directed therapy remains elevated.
Clinical, anatomic, and histologic determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis: A cohort study of 560 patients
Steinhardt, Max, Muchtar, Eli, Kourelis, Taxiarchis, Warsame, Rahma, Mauermann, Michelle, Buadi, Francis, Dingli, David, Leung, Nelson, Cook, Joselle, Go, Ronald, Hayman, Suzanne, Gonsalves, Wilson, Kapoor, Prashant, Zanwar, Saurabh, Binder, Moritz, Hellou, Tamer, Tan, Melinda, Fonder, Amie, Hobbs, Miriam, Abdallah, Nadine, Lin, Yi, Siddiqui, Mustaqeem, Kyle, Robert, Einsele, Hermann, Rajkumar, S. Vincent, Kumar, Shaji, Kortüm, K. Martin, Gertz, Morie, Dispenzieri, Angela, Mauermann, Michelle L. , Mauermann, Michelle L , Steinhardt, Max, Muchtar, Eli, Kourelis, Taxiarchis, Warsame, Rahma, Buadi, Francis, Dingli, David, Leung, Nelson, Cook, Joselle, Go, Ronald, Hayman, Suzanne, Gonsalves, Wilson, Kapoor, Prashant, Zanwar, Saurabh, Binder, Moritz, Hellou, Tamer, Tan, Melinda, Fonder, Amie, Hobbs, Miriam, Abdallah, Nadine, Lin, Yi, Siddiqui, Mustaqeem, Kyle, Robert, Einsele, Hermann, Rajkumar, S. Vincent, Kumar, Shaji, Kortüm, K. Martin, Gertz, Morie, Dispenzieri, Angela

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3962-3962

10.1182/blood-2025-3962 Get It

Abstract Background: Gastrointestinal (GI) symptoms are frequent in patients (pts) with systemic light chain amyloidosis (AL), yet their clinical significance remains poorly defined. We investigated the role of symptomatic GI involvement in disease burden, survival, and organ-specific outcomes in a large single-center cohort. Methods From 2010–2025, 4,396 AL pts were evaluated at our center; 560 pts (13%) had provider-attributed symptomatic GI AL. Pts with localized AL or positive biopsy without GI symptoms were excluded (n=38). We analyzed relationships between GI symptoms, anatomic/histologic involvement, laboratory parameters, survival, and need for nutritional support using Wilcoxon rank-sum, Chi-square, Kaplan-Meier, and logistic regression tests. Results GI symptoms included early satiety (n=320/57%), diarrhea (n=189/34%), nausea (n=184/33%), abdominal pain (n=148/26%), dysphagia (n=119/21%), vomiting (n=75/13%), GI bleeding (n=74/13%), and heartburn (n=71/13%). Only nausea and GI bleeding were not associated with cardiac (n=366/65%) renal (n=274/49%) or hepatic (n=84/15%) AL, whereas dysphagia, early satiety and heartburn were more frequent with cardiac (all OR=1.7), abdominal pain and diarrhea with hepatic (OR=2 and 1.6, respectively), and vomiting with renal involvement (OR=2; all p<0.04). Autonomic involvement impacted GI symptoms, often without proof of parenchymal GI amyloid. Of the 124 pts with formal autonomic testing, only 44 (35%) had positive GI biopsies as compared to AL GI pts without proven autonomic involvement (240/436, 55%). Pts with autonomic involvement were more symptomatic than pts with positive GI biopsies, suffering more often from dysphagia (29% vs 19%), diarrhea (41% vs 32%), and gastroparesis (34% vs 9%, all p<0.001). We screened changes in body weight, calcium, VitB12, Hb, PO4, and albumin at diagnosis. Of the 175 pts with documented weight loss in this cohort, pts with GI AL lost more weight compared to those with other organ involvement (21% vs 14% of weight, p=0.002), and had lower phosphate (3.7 vs 4.0 mg/dL, p=0.06). In our cohort of pts with GI symptoms, 298 (53%) had a positive GI biopsy. Biopsy-proven anatomic involvement dictated symptoms (all p<0.05): Of the 20 pts with positive esophageal biopsy, dysphagia was present in 45%; only 33% of the pts without an esophageal biopsy had dysphagia. Similar patterns were seen for the 170 pts with a positive gastric biopsy (n=170) in terms of heartburn (21% vs 11%), for the 165 pts with positive small bowel biopsies in terms of abdominal pain (68% vs 32%), and for the 130 pts with positive colon biopsies and diarrhea (46% vs 33%). Specific histopathological patterns were prognostic. Mucosal involvement (n=161) was an independent risk factor for survival compared to submucosal (n=64) and vascular (n=102) involvement throughout the GI tract (HR 1.83; p=0.03). Three-layer GI infiltration was associated with inferior mOS (2.4 vs 5.1 vs 7.8 y for 3 vs 2 vs 1-layer involvement, HR 3.19/1.56/1; p<0.05). Counterintuitively, vascular involvement had the lowest risk of bleeding in all GI anatomic sites (p=0.02). In the colon, only mucosal involvement was associated with a higher risk of bleeding (OR=5; p=0.04). GI involvement in AL pts did not worsen prognosis (mOS 10.0/6.3y, p=0.02), and pts with isolated GI AL (n=74/13%) had an even better survival (55% surviving at 10 y). Cachexia (n=120; mOS 3.5 vs 7.8 y, p<0.001), need for nutritional support (n=36; mOS 0.9 vs 7.0 y, p<0.001), and diarrhea (mOS 5.8 vs 6.9 y, p=0.06) were risk factors for death. In pts with hematologic response (≥PR), bleeding did not recur within 3 y (n=27), but even with response, diarrhea (n=160) persisted in 39%. Resolution was less frequent without hematologic response (persistence in 69%, OR=3.5). Improvement was most often due to treatment of bacterial overgrowth (11/35 pts; 68%) and loperamide (54/59 pts; 91%). Conclusion In AL, meaningful GI involvement is defined by nausea, diarrhea, occurrence of bleeding, and malnutrition. These are primarily associated with mucosal infiltration. GI symptoms can occur in the face of autonomic involvement. While long-term persistence of GI bleeding is rare after serologic response, cachexia and persistent diarrhea drive morbidity, need for nutritional support, and poor survival.
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib
Meyerhardt, Jeffrey A. , Twombly, Tyler S., Pederson, Levi , Väyrynen, Juha P. , Zhao, Melissa , Shergill, Ardaman , Kumar, Pankaj , Couture, Felix, Kuebler, Philip , Krishnamurthi, Smitha , Giannakis, Marios , Ogino, Shuji, Sharma, Shruti, Aleshin, Alexey , Shields, Anthony F. , Kuebler, J. Philip , Meyerhardt, Jeffrey A , Väyrynen, Juha , Zhang, George Q. , Shi, Qian , Ma, Chao , Takashima, Yasutoshi , Couture, Felix, Tan, Benjamin, O’Reilly, Eileen M. , Ogino, Shuji , Jurdi, Adham Adel , Sharma, Shruti , Nowak, Jonathan A.

Mayo Clinic

JAMA Oncology | December 4, 2025 | Volume: 12 | Issue: 2 | Pages: 149

10.1001/jamaoncol.2025.5144 | PMID 41343176 Get It

Importance Observational studies have associated use of aspirin and selective cyclooxygenase inhibitors with decreased recurrence and improved survival in patients with colon cancer. While randomized clinical trials have not shown benefit across all patients, these findings suggest that select subgroups may benefit from their use. Despite the well-established prognostic value of circulating tumor DNA (ctDNA), its role in guiding treatment remains unclear. Objective To investigate the predictive value of postoperative ctDNA for survival outcomes with adjuvant celecoxib alongside conventional chemotherapy in patients with stage III colon cancer. Design, Setting, and Participants This was a post hoc analysis of the phase 3 Cancer and Leukemia Group B (now Alliance)/Southwest Oncology Group 80702 randomized clinical trial (2010-2015) assessing adjuvant celecoxib vs placebo and 3 vs 6 months of adjuvant 5-fluorouracil, leucovorin, and oxaliplatin for stage III colon cancer. Patients consented to biospecimen collection and had ctDNA analysis performed. Data analysis was performed from September 2024 to June 2025. Exposures Postoperative ctDNA positivity was determined using a clinically validated, tumor-informed 16-plex-polymerase chain reaction-next-generation sequencing assay (Signatera; Natera Inc) performed between surgery and initiation of adjuvant therapy. Main Outcomes and Measures Disease-free survival (DFS) and overall survival (OS). Survival by ctDNA status and adjuvant celecoxib use were assessed as part of a post hoc companion study with prespecified statistical analysis plan. Results Among 940 patients (mean [SD] age, 60.9 [10.8] years; 426 female [45.3%] and 515 male [54.7%] individuals; 222 [23.6%] with prior low-dose aspirin use; and median follow-up of 6.0 [95% CI, 6.0-6.0] years), 767 (81.6%) were ctDNA negative and 173 (18.4%) were ctDNA positive. ctDNA positivity was highly prognostic of worse DFS (reference, ctDNA negativity; adjusted hazard ratio [aHR], 6.12; 95% CI, 4.66-8.03) and OS (aHR, 5.86; 95% CI, 4.19-8.19). In patients with ctDNA positivity, celecoxib was associated with improved DFS (aHR, 0.61; 95% CI, 0.42-0.89) and OS (aHR, 0.62; 95% CI, 0.40-0.96) compared to placebo. Among patients with ctDNA negativity, celecoxib did not provide survival benefit (DFS: aHR, 0.76; 95% CI, 0.53-1.09; OS: aHR, 0.85; 95% CI, 0.54-1.36), although the interaction was not significant ( P for interaction, .41 and .33 for DFS and OS, respectively). These findings persisted when stratifying patients by microsatellite instability status and PIK3CA mutational status. Conclusion and Relevance The findings of this post hoc analysis suggest that ctDNA status has the potential to inform clinical decision-making among patients with stage III colon cancer who should consider adjuvant celecoxib in addition to conventional chemotherapy. Trial Registration ClinicalTrials.gov Identifier: NCT01150045